Tissue factor-dependent and -independent pathways of systemic coagulation activation in acute myeloid leukemia: a single-center cohort study by unknown




and -independent pathways of systemic 
coagulation activation in acute myeloid 
leukemia: a single-center cohort study
Christina Dicke1†, Ali Amirkhosravi2†, Brigitte Spath1, Miguel Jiménez‑Alcázar3, Tobias Fuchs3, Monica Davila2, 
John L Francis2, Carsten Bokemeyer1 and Florian Langer1*
Abstract 
Background: In acute myeloid leukemia (AML), disseminated intravascular coagulation (DIC) contributes to morbid‑
ity and mortality, but the underlying pathomechanisms remain incompletely understood.
Methods: We conducted a prospective study on 69 patients with newly diagnosed AML to further define the cor‑
relates of systemic coagulation activation in this hematological malignancy. Tissue factor procoagulant activity (TF 
PCA) of isolated peripheral blood mononuclear cells (PBMCs) and TF expression by circulating microparticles (MPs) 
were assessed by single‑stage clotting and thrombin generation assay, respectively. Soluble plasma TF antigen and 
secretion of vascular endothelial growth factor (VEGF) by cultured PBMCs were measured by ELISA. Cell‑free plasma 
DNA was quantified by staining with a fluorescent dye.
Result: TF PCA of PBMCs was significantly increased in AML patients as compared to healthy controls. Furthermore, 
TF PCA was significantly associated with decompensated DIC at presentation, as defined by a plasma fibrinogen level 
of ≤1 g/L (n = 11). In addition to TF PCA and circulating blasts, serum lactate dehydrogenase, a surrogate marker for 
leukemic cell turnover, correlated with plasma D‑Dimer in the total patient cohort and was significantly increased 
in DIC patients, suggesting a role for myeloblast apoptosis/necrosis in activation of the TF‑dependent coagulation 
pathway. Consistently, TF‑bearing plasma MPs were more frequently detected and levels of soluble TF antigen were 
significantly higher in DIC vs. non‑DIC patients. No association was found between TF PCA expression and VEGF 
secretion by isolated PBMCs, but significantly increased levels of cell‑free plasma DNA pointed to a contribution of the 
intrinsic contact pathway to systemic coagulation activation in the total patient cohort and in patients with lower TF 
PCA expression. While PBMC‑associated TF PCA had no effect on long‑term survival, DIC occurrence at presentation 
increased the risk of early mortality.
Conclusion: In newly diagnosed AML, TF expression by PBMCs and shedding of TF‑bearing plasma MPs are central 
to the pathogenesis of DIC, but additional pathways, such as DNA liberation, may contribute to systemic coagulation 
activation.
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Background
Acute myeloid leukemia (AML) is a highly aggressive 
hematological malignancy characterized by clonal expan-
sion of transformed myeloblasts. Patients with AML are 
at increased risk for both hemorrhagic and thromboem-
bolic complications [1–3]. Besides disease- or treatment-
related thrombocytopenia, AML patients may suffer 
from complex systemic coagulopathies such as overt dis-
seminated intravascular coagulation (DIC), excessive 
fibrinolysis, or non-specific proteolysis. In particular, 
patients with acute promyelocytic leukemia (APL) are 
at substantial risk for a thrombohemorrhagic syndrome 
that, despite modern anti-leukemic therapy, still signifi-
cantly contributes to early morbidity and mortality [4].
In newly diagnosed AML, potentially large numbers of 
myeloblasts circulate in direct contact with the plasma 
compartment. It is thus very likely that the procoagu-
lant (or fibrinolytic) phenotype of AML blasts will have 
a profound effect on the hemostatic system. In fact, early 
studies have implicated over-expression of tissue factor 
(TF), the principal initiator of the extrinsic coagulation 
protease cascade, in the pathogenesis of AML-associated 
DIC [5–8]. More recent studies, however, have ques-
tioned the relevance of TF-driven coagulation activation 
to the hypercoagulable state in various hematological 
malignancies, including AML, and suggested alternative 
mechanisms such as acquired activated protein C resist-
ance [9, 10].
Because a thorough understanding of the cellular and 
molecular pathways underlying AML-associated DIC 
is mandatory to identify novel drug targets for the pre-
vention and treatment of potentially fatal thrombohe-
morrhagic events, we conducted a prospective study to 
further define the correlates of systemic coagulation acti-
vation in 69 patients with newly diagnosed AML.
Results
Patient population
The primary study population comprised 69 patients 
with newly diagnosed AML (Table 1). The mean age was 
59  ±  16  years, and 61% of study subjects were males. 
While 56 patients (81%) had de-novo (i.e. primary) AML, 
including five patients with APL (M3), 13 patients (19%) 
had secondary AML resulting from either myelodys-
plastic syndrome (MDS) or myeloproliferative neoplasia 
(MPN).
TF PCA of PBMCs is increased in AML
We used a single-stage clotting assay to measure TF-
specific procoagulant activity (TF PCA) in intact and 
disrupted PBMCs. In the total AML patient cohort 
(n  =  69), TF PCA was significantly increased in dis-
rupted as compared to intact PBMCs (median TF PCA, 
696 vs. 293 AU/106 cells, P < 0.001) (Fig. 1a), indicating 
that a significant proportion of the TF PCA was latent 
(or cryptic) on unperturbed cells. In five AML patients 
(7%), TF PCA was undetectable on intact PBMCs, but 
could be decrypted by cell disruption in four of them. 
In the remaining patient, however, TF PCA was absent 
both before and after cell disruption. In the 64 patients 
with measurable TF PCA on intact PBMCs, cell disrup-
tion resulted in an average 5.1-fold increase in cellular 
TF PCA. In the total study cohort (n = 69), there was a 
significant correlation between TF PCA of intact and dis-
rupted PBMCs (r = 0.80; P < 0.001).
TF PCA of PBMCs was significantly increased in 
AML patients (n = 69) as compared to healthy controls 
(n = 10) (Fig. 1a), suggesting that leukemic transforma-
tion was associated with upregulation of the TF-depend-
ent coagulation pathway. However, PBMC-associated TF 
PCA varied widely among study subjects with 50 AML 
patients (72%) having TF PCA levels within the reference 
range, the upper limit of which was defined as the 95th 
percentile of TF PCA levels of intact PBMCs within the 
control group. To compare PBMC-associated TF PCA 
expression in newly diagnosed AML with that in other 
Table 1 Demographic, clinical and  laboratory characteris-
tics of AML patients
Data are presented as mean ± standard deviation or as median and interquartile 
range. AML subtypes are according to the French–American–British (FAB) 
classification.
APL acute promyelocytic leukemia, LDH lactate dehydrogenase, MDS 
myelodysplastic syndrome, MPN myeloproliferative neoplasia.
Normal range Patients (n = 69)
Age (years) 59 ± 16
Gender
 Male 42 (61%)
 Female 27 (39%)
AML
 Primary 56 (81%)
  M0/M1/M2 32
  M3 (APL) 5
  M4/M5 19
  M6/M7 0
 Secondary 13 (19%)
  Post MDS 12
  Post MPN 1
Peripheral blasts (103/µL) 12 (2–30)
Platelets (103/µL) 150–400 47 (25–88)
Hemoglobin (g/dL) 12.3–15.3 9.6 ± 1.9
Prothrombin time (%) 80–130 79 ± 23
Fibrinogen (g/L) 1.8–4.0 4.3 ± 2.3
D‑dimer (mg/L) 0.0–0.5 5.1 (1.6–22.1)
LDH (U/L) 84–246 474 (339–884)
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hematological malignancies, we also studied patients 
with MDS or acute lymphoblastic leukemia (ALL). There 
were no statistically significant differences in median TF 
PCA levels between AML patients (n = 69) and patients 
with either MDS (n  =  7) or ALL (n  =  5), albeit none 
of the latter patients had a PBMC-associated TF PCA 
level of >1,500 AU/106 cells (Fig. 1a). Collectively, these 
findings indicate that PBMC-associated TF PCA is over-
expressed at least in a subgroup of patients with newly 
diagnosed AML.
TF PCA expression among FAB subtypes
To analyze PBMC-associated TF PCA expression 







































































































































Fig. 1 Expression of tissue factor‑specific procoagulant activity (TF PCA) by peripheral blood mononuclear cells (PBMCs) and markers of systemic 
coagulation activation. a PBMCs were isolated from patients with newly diagnosed acute myeloid leukemia (AML), acute lymphoblastic leukemia 
(ALL), or myelodsyplastic syndrome (MDS) and analyzed for TF PCA, expressed as arbitrary units (AU), by single‑stage clotting assay both before 
(intact) and after repeated freeze–thawing (disrupted). The dashed line indicates the upper limit of the reference range for TF PCA of intact PBMCs 
as determined by analysis of ten healthy controls. P values are according to Mann–Whitney U test. b Levels of PBMC‑associated TF PCA according 
to FAB subtypes. P value is according to Kruskal–Wallis test. For illustration purposes only, data points with “zero” TF PCA were plotted as 1 AU/106 
PBMCs in panels a and b. c In a subgroup of 20 patients, plasma levels of both D‑dimer and thrombin–antithrombin (TAT) complexes were 
measured at initial presentation. Correlation coefficient and P value are according to the method of Spearman. d In two patients, D‑dimer and TAT 
plasma levels were measured at presentation and during AML remission. e D‑dimer plasma levels according to FAB subtypes. P value is according to 
Kruskal–Wallis test.
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classification, AML patients (n  =  69) were grouped in 
those with M0/M1/M2 (n  =  32), M3 (n  =  5), M4/M5 
(n  =  19) or secondary AML (n  =  13) (Fig.  1b). When 
compared to healthy controls, TF PCA levels of both 
intact and disrupted PBMCs were significantly increased 
in each of these subgroups [not shown]. When compared 
among each other, patients with APL (M3) had signifi-
cantly higher TF PCA levels than patients included in the 
other subgroups, although values of PBMC-associated 
TF PCA were overlapping with those in the M0/M1/M2 
and M4/M5, but not with those in the secondary AML 
subgroup (Fig. 1b).
Markers of systemic coagulation activation
Because plasma D-dimer is readily available and widely 
used in clinical practice and part of the SSC/ISTH DIC 
score [11], this parameter was chosen to assess sys-
temic coagulation activation in our study. However, 
D-dimer originates from plasmin-mediated degradation 
of cross-linked fibrin and therefore reflects fibrinolytic 
rather than procoagulant activity. In contrast, circulat-
ing thrombin–antithrombin (TAT) complexes are a more 
accurate marker of in  vivo thrombin generation. To 
investigate the usefulness of D-dimer as a hemostatic 
activation marker in newly diagnosed AML, we addition-
ally measured circulating TAT complexes in a subgroup 
of 20 AML patients, the selection of which was based on 
the degree of D-dimer elevation (low vs. high) and avail-
ability of plasma samples. In this subgroup, there was a 
quite strong correlation between the two parameters 
(Fig. 1c). Follow-up plasma samples were available from 
two patients achieving complete hematological remission 
after the first cycle of induction chemotherapy. Plasma 
levels of D-dimer and TAT complexes either normalized 
or decreased close to normal in both patients (Fig.  1d), 
further indicating that plasma D-dimer may be an appro-
priate marker of systemic coagulation activation in newly 
diagnosed AML, particularly in the absence of recent 
surgery, acute infections, and relevant organ dysfunc-
tions, all of which were exclusion criteria in our study 
(see section “Methods”).
When analyzing the total AML patient cohort (n = 69), 
only two patients (3%) had D-dimer plasma levels within 
the reference range (i.e. <0.5  mg/L). Similar to PBMC-
associated TF PCA, plasma D-dimer levels were highest 
in the M3 subgroup, but levels exceeding 30 mg/L were 
also observed in the M0/M1/M2 and M4/M5 subgroups 
(Fig. 1e).
Role of cellular TF PCA in DIC evolution
Of the 69 AML patients, 11 (16%) presented with a 
(thrombo)hemorrhagic syndrome due to decompensated 
DIC, as defined by a plasma fibrinogen level of ≤1  g/L 
(referred to as DIC hereafter) (Table  2). In non-DIC 
patients (n = 58), the median plasma fibrinogen level was 
4.7 g/L (range, 1.8–9.9 g/L). All DIC patients had primary 
AML, and APL (M3) was the diagnosis in four of them. 
Thus, one of the five APL patients included in this study 
had no DIC at presentation. Of the remaining seven DIC 
patients, three had acute (myelo)monocytic leukemia 
(M4/M5) and four had AML M1 or M2.
In the total AML patient cohort (n = 69), plasma lev-
els of D-dimer significantly correlated with TF PCA of 
intact (Fig. 2a) and disrupted PBMCs (Fig. 2b), absolute 
numbers of circulating blasts (Fig. 2c), and lactate dehy-
drogenase (LDH) serum levels (Fig. 2d). However, while 
expression of PBMC-associated TF PCA beyond a certain 
level (i.e. >2,500 AU/106 intact PBMCs or >8,000 AU/106 
disrupted PBMCs) was inevitably associated with DIC, 
no such association was observed for peripheral blasts or 
LDH (Fig. 2).
Levels of PBMC-associated TF PCA were signifi-
cantly increased in DIC patients (n =  11) as compared 
to non-DIC patients (n = 58), both before and after cell 
disruption (Fig. 3a). While there was no difference with 
regard to absolute numbers of circulating blasts between 
the two groups (Fig.  3b), patients with DIC had signifi-
cantly higher LDH serum levels (Fig. 3c). These findings 
may indicate that, in addition to TF PCA expression by 
transformed myeloblasts, leukemic cell apoptosis/necro-
sis significantly contributed to the development of DIC in 
patients with newly diagnosed AML.
TF PCA of plasma microparticles is associated with DIC
Because microparticles (MPs) are known to be released 
during apoptosis/necrosis, we measured circulating TF-
bearing MPs in DIC and non-DIC patients using a quali-
tative thrombin generation assay (TGA) (Fig. 4a). Plasma 
for MP isolation was not available from two patients with 
DIC and one patient without DIC. TF-bearing plasma 
MPs were detectable in six out of nine DIC patients (67%) 
and in eleven out of 57 non-DIC patients (19%) (Fig. 4b). 
Interestingly, all three of the APL patients with DIC from 
whom plasma samples were available were tested posi-
tive for TF-bearing plasma MPs (Table  2), but not the 
one APL patient without DIC. These findings indicate 
that DIC evolution in newly diagnosed AML is associ-
ated with increased shedding of TF-bearing plasma MPs. 
We also measured soluble TF antigen in plasma samples 
available from 63 AML patients, including eight patients 
with DIC. While there was no significant difference in 
plasma TF antigen levels between AML patients (n = 63) 
and healthy controls (n = 10), DIC patients (n = 8) had 
significantly higher levels than non-DIC patients (n = 55) 
and controls (Fig. 4c), further indicating that TF expres-
sion is upregulated in AML-associated DIC.
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Cellular TF PCA is not correlated with VEGF secretion
Experimental and clinical evidence indicates that angio-
genesis and coagulation activation (i.e. TF expression) 
are closely interrelated in patients with solid malignan-
cies [12]. Because increased VEGF and bone marrow 
microvessel density have also been reported in AML 
[13–16], we explored such a relationship in our study 
cohort. To this end, VEGF antigen levels were measured 
in plasmas and culture supernatants, which were avail-
able from 46 and 45 of the AML patients, respectively. 
There was no difference in VEGF plasma levels between 
patients and controls (Fig. 5a). There was also no statis-
tically significant difference in VEGF antigen levels in 
culture supernatants between the two groups. However, 
17 of the studied 45 AML patients (38%) had VEGF anti-
gen levels of >40 pg/mL, whereas all control subjects had 
VEGF antigen levels of <40 pg/mL (Fig. 5a). We used this 
arbitrary cut-off value to investigate, if VEGF secretion 
by isolated PBMCs was associated with cell-associated 
TF PCA, but no such association could be found, neither 
for intact nor for disrupted PBMCs (Fig. 5b).
Potential role of cell-free DNA in intravascular coagulation 
activation
Recently, neutrophil extracellular traps (NETs) have 
been identified as activators of blood coagulation [17, 
18]. Furthermore, NETs are associated with various 
cancer-associated clotting disorders [19], including 
deep-vein thrombosis and thrombotic microangiopa-
thies [20–22]. DNA is a major component of NETs and 
sufficient to accelerate blood clotting [23]. We therefore 
asked if increased levels of cell-free DNA could account 
for systemic coagulation activation, as assessed by 
plasma D-dimer, in our AML patient cohort. Plasma for 
DNA quantification was not available from four AML 
patients, including three patients with DIC. Compared 
to healthy controls (n = 10), AML patients (n = 65) had 
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Fig. 2 Correlations of PBMC‑associated TF PCA, circulating blasts, and serum lactate dehydrogenase (LDH) with plasma D‑dimer. Cellular TF 
PCA was measured by single‑stage clotting assay using both intact (a) and disrupted PBMCs (b). Absolute numbers of circulating blasts (c) were 
calculated by multiplying the automatically determined white blood cell count with the percentage of myeloblasts on peripheral blood smears. 
LDH serum levels (d) were determined by standard laboratory techniques. Correlation coefficients and P values are according to the method of 
Spearman. The horizontal dashed lines in panels a and b indicate thresholds above which TF PCA levels were inevitably associated with decompen‑
sated DIC and a (thrombo)hemorrhagic syndrome as observed in eleven patients (red data points). The LDH serum level was not available from one 
patient with DIC.
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(Fig.  5c). In AML patients, extracellular DNA levels 
significantly correlated with plasma D-dimer (r =  0.31, 
P =  0.011) and serum LDH (r =  0.37, P =  0.002), but 
not with peripheral blasts (r  =  0.22, P  =  0.080). To 
further explore the relevance of cell-free DNA for sys-
temic coagulation activation, AML patients (n  =  65) 
were grouped into those with plasma DNA levels of 
>110  ng/mL (n  =  43), corresponding to the 95th per-
centile of plasma DNA levels within the control cohort, 
and those with plasma DNA levels of ≤110  ng/mL 
(n =  22). Patients with cell-free DNA levels above this 
cut-off value had significantly increased plasma D-dimer 
(Fig. 5d). In a subsequent analysis, we excluded all DIC 
patients with TF PCA levels of intact PBMCs exceed-
ing 2,500 AU/106 cells (n = 7), because in these patients, 
expression of TF PCA was considered the predominant 
cause of systemic coagulation activation (Fig. 2a). In this 
modified study population (n = 58), plasma DNA levels 


































































Fig. 3 Evolution of DIC in newly diagnosed AML is associated with increased TF PCA and serum LDH. a TF PCA was measured by single‑stage 
clotting assay using both intact and disrupted PBMCs. Peripheral blasts (b) and serum LDH (c) were determined as described above. For illustration 
purposes only, data points with “zero” peripheral blasts were plotted as 0.1/µL. P values are according to Mann–Whitney U test. The LDH serum level 
was not available from one patient with DIC.
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Effect of TF PCA on clinical outcome
In the total AML patient cohort (n = 69), median (mOS) 
and 5-year overall survival (OS) was 6.9  months and 
29.9%, respectively (Fig. 6a). Increased VEGF expression 
has been associated with a more aggressive phenotype 
and an unfavorable clinical outcome in AML [14]. We 
therefore first analyzed our patient cohort with respect to 
ex vivo VEGF production. Patients with increased VEGF 
production (i.e. VEGF antigen in culture supernatant, 
>40  pg/mL) had a shorter mOS (4.8 vs. 11.7  months) 
and a decreased OS (23.5 vs. 32.1%) than patients with 
no appreciable VEGF production (i.e. VEGF antigen, 
≤40  pg/mL) (Fig.  6b). Although this difference did not 
reach statistical significance, which was likely due to the 
relatively small sample size, it is consistent with the pos-
tulated role of VEGF in AML biology.
In contrast, no difference was found for mOS or OS, 
when AML patients were stratified according to the TF 
PCA level of intact PBMCs using either 735 AU/106 cells 
(corresponding to the 95th percentile of TF PCA levels 
within the control group) or 293  AU/106 cells (corre-
sponding to the median TF PCA level within the patient 
cohort) as the cut-off value (Fig. 6c, d). While the pres-
ence of DIC at presentation did not adversely affect OS 
(Fig. 6e), it was significantly associated with early mortal-
ity (Fig. 6f ).
Discussion
In this study, we investigated PBMC-associated TF PCA 
in 69 patients with newly diagnosed AML and found that 
TF PCA expression beyond a critical level was inevitably 







































































































Fig. 4 Microparticle‑associated TF PCA and soluble plasma TF antigen are associated with decompensated DIC in newly diagnosed AML. Micro‑
particles (MPs) were isolated from plasma and analyzed for TF PCA by thrombin generation assay as described under the section “Methods”. a 
Representative thrombin generation curves from two patients tested positive (TF+) or negative (TF−) for MP‑associated TF PCA are shown (αTF, 
inhibitory TF antibody). b Proportions of patients tested positive for MP‑associated TF PCA in the DIC and non‑DIC cohorts are indicated by the black 
columns. P value is according to Fisher’s exact test. Plasma for MP isolation was not available from two patients with DIC and one patient without 
DIC. c A commercial ELISA was used to measure soluble TF antigen levels in plasma that was not available from three DIC and two non‑DIC patients. 
P values are according to Mann–Whitney U test.
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Importantly, DIC was not restricted to APL patients, but 
also occurred in seven other patients, three of whom had 
acute (myelo)monocytic leukemia. To our knowledge, 
this is one of the largest prospective studies so far specifi-
cally addressing the determinants of systemic coagulation 
activation in newly diagnosed AML.
The increase in PBMC-associated TF PCA following 
cell disruption is consistent with the concept of cryptic 
TF that can be de-encrypted upon cellular activation 
or induction of apoptosis/necrosis [24]. Previous stud-
ies have clearly shown that cryptic TF is entirely cell 
surface-expressed on (myelo)monocytic cells and not 
liberated from intracellular storage pools upon cell lysis 
[25–27]. Instead, negatively charged phospholipids (i.e. 
phosphatidylserine) exposed on the outer membrane 
leaflet act synergistically with thiol-disulfide exchange 
reactions to activate surface-expressed TF [28–30]. In 
this regard, our findings provide circumstantial clini-
cal evidence that membrane alterations associated with 
apoptosis/necrosis indeed contribute to cellular TF acti-
vation in  vivo, because serum LDH levels, a surrogate 
marker for leukemic cell turnover, significantly correlated 
with plasma D-dimer. Systemic coagulation activation in 
AML is thus, at least to a substantial extent, determined 
by the following three factors: specific upregulation of 






































































































Fig. 5 Associations of VEGF and cell‑free plasma DNA with TF PCA expression and systemic coagulation activation. a Vascular endothelial growth 
factor (VEGF) antigen levels were measured in plasma or PBMC culture supernatants by ELISA. b Based on VEGF antigen levels in culture super‑
natants, AML patients were grouped into those with (>40 pg/mL) and those without (≤40 pg/mL) appreciable VEGF production. No significant 
differences were found with regard to TF PCA levels in intact or disrupted PBMCs. c Levels of cell‑free plasma DNA were quantified in patients and 
controls as described under the section “Methods”. Plasma for DNA quantification was not available from four patients with AML. d Based on levels 
of cell‑free plasma DNA, patients were grouped into those with DNA levels greater or equal or less than the cut‑off value of 110 ng/mL defined by 
the 95th percentile within the control group. e In a modified analysis, the seven AML patients with DIC and TF PCA levels of intact PBMCs exceeding 
2,500 AU/106 cells were excluded. P values are according to Mann–Whitney U test.
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hematopoietic stem cells, elevated numbers of circulating 
blasts, and a significant degree of spontaneous apopto-
sis/necrosis. In our study, none of the patients developed 
overt DIC after the implementation of induction chemo-
therapy, which may de-encrypt cellular TF through the 
above mechanisms [26, 29]. Interestingly, in DIC patient 
no. 11 (Table 2), the systemic coagulopathy resolved dur-
ing phases of AML remission, but recurred simultane-
ously with fulminant AML relapse, suggesting that the 
procoagulant phenotype of myeloblasts may be preserved 
despite intensive anti-leukemic therapy, including allo-
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Fig. 6 Impact of VEGF production, TF PCA expression and DIC evolution on overall survival. a Overall survival of the total AML patient cohort 
(n = 69). The dashed lines indicate the 95% confidence interval. b Overall survival of AML patients grouped according to VEGF antigen levels in cul‑
ture supernatants. c, d Overall survival of AML patients grouped according to TF PCA levels of intact PBMCs. Cut‑off values for TF PCA were defined 
as the 95th percentile within in the control group (c) or as the median within the patient cohort (d). e Overall survival of AML patients grouped 
according to the presence of DIC at presentation. f Survival analysis of DIC and non‑DIC patients who died during the observation period.
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Our findings also point to a role of circulating TF-
bearing MPs in the pathogenesis of AML-associated 
DIC, which has most recently been suggested by other 
experimental and clinical observations [31–33]. Shed-
ding of MPs typically results from cellular activation or 
apoptosis, but may occur spontaneously in solid cancers 
and hematological malignancies [34]. Although MP-asso-
ciated TF PCA was more frequently detected in DIC as 
compared to non-DIC patients, our findings do not allow 
the conclusion that shedding of TF-bearing MPs alone 
was sufficient to cause overt DIC in newly diagnosed 
AML. However, caution is warranted when comparing 
results of different studies due to a lack of standardized 
assays to measure MP TF.
The finding that plasma TF antigen was significantly 
increased in DIC as compared to non-DIC patients and 
healthy controls may be interpreted in favor of our con-
clusion that TF is an important determinant of DIC 
evolution in newly diagnosed AML. It is important to 
note, however, that solid-phase immunoassays may 
preferentially capture soluble (i.e. truncated) TF, which 
is functionally inactive, rather than MP-associated TF. 
Furthermore, there is concern about a lack of specificity 
when using human plasma in commercial TF ELISAs, 
which may result in inappropriately high background 
signals [35, 36]. Nevertheless, in our study, plasma TF 
antigen was specifically upregulated in patients with DIC 
(Fig. 4c). Because the commercial TF ELISA used in our 
study does not detect alternatively spliced TF (unpub-
lished data), future studies should therefore investigate, if 
proteolytic degradation of full-length TF by enzymes lib-
erated from dying myeloblasts represents a novel mecha-
nism of controlling the extrinsic coagulation pathway in 
newly diagnosed AML. Taken together, functional assays 
are more sensitive and specific than ELISAs in detecting 
minute amounts of biologically active TF, but TF immu-
noassays may provide useful complementary information 
in complex disease states.
An important finding of our study is that significant 
systemic coagulation activation, as indicated by exces-
sively elevated plasma D-dimer, may occur in the absence 
of TF PCA overexpression by PBMCs. In fact, three of 
the eleven DIC patients (27%) had TF PCA levels below 
the threshold values of 2,500 AU/106 cells for intact and 
8,000  AU/106 cells for disrupted PBMCs (Fig.  2). All of 
these patients had quite high numbers of circulating 
blasts, but two of them had only moderately increased 
serum LDH levels (Table  2). These observations point 
to alternative cellular and molecular pathways con-
tributing to systemic coagulation in newly diagnosed 
AML. In this regard, negatively charged polymers such 
as polyphosphates or nucleic acids (i.e. RNA and DNA) 
have recently been identified as key mediators of intrinsic 
contact pathway activation in vivo [37]. Consistent with 
a highly aggressive hematological malignancy leading to 
substantial spontaneous cell death, we found significantly 
increased levels of cell-free plasma DNA in the AML 
patient cohort. Furthermore, DNA levels correlated with 
plasma D-dimer and serum LDH. Even when the seven 
DIC patients with exceedingly high PBMC-associated 
TF PCA were excluded, levels of cell-free plasma DNA 
were associated with the degree of systemic coagulation 
activation (Fig.  5e). These findings may be regarded as 
circumstantial clinical evidence that liberation of DNA 
from apoptotic/necrotic AML blasts indeed contributes 
to intravascular thrombin generation through contact 
activation of factor XII [38] and may thus stimulate fur-
ther research into the role of the intrinsic coagulation 
pathway in AML-associated coagulopathies. It has to be 
noted, however, that we did not specifically consider the 
contribution of cytoplasmic RNA [23], which may be lib-
erated from dying cells at an earlier stage than nuclear 
DNA and which may be more closely correlated with 
serum LDH levels. Nevertheless, DNA-mediated acti-
vation of factor XII could explain why other studies did 
not find a significant contribution of the TF-dependent 
coagulation pathway to systemic coagulation activation 
in various hematological malignancies, including AML 
[9, 10]. Another potential mediator of PCA in AML is 
cancer procoagulant (CP), a cysteine proteinase that acti-
vates factor X independently of factor VIIa (FVIIa) [39], 
although more recent studies have questioned a predom-
inant role of CP in paraneoplastic coagulation activation 
[40].
In solid malignancies, TF expression has been linked 
to tumor angiogenesis. In particular, TF has been shown 
to regulate VEGF production via its cytoplasmic domain 
[41], and TF-FVIIa-mediated cell signaling through 
cleavage of protease-activated receptor-2 (PAR-2) is cru-
cial to neoplastic blood vessel formation [42]. Although 
such a relationship has also been postulated for hemato-
logical malignancies [43–45], our findings do not support 
an obvious association between TF PCA expression and 
VEGF secretion by isolated PBMCs in newly diagnosed 
AML. It has to be noted, however, that TF PCA, as meas-
ured in our study, is not directly coupled to TF signaling 
functions, because cryptic (i.e. non-coagulant) TF still 
binds FVIIa and thus retains its ability to activate PAR-2 
[46]. Furthermore, measurement of ex  vivo VEGF pro-
duction by isolated PBMCs may not adequately reflect 
bone marrow microvessel density, which is also likely 
dependent on additional angiogenic growth factors (e.g. 
bFGF, HGF) not addressed in our study [16].
Patients presenting with DIC had a higher probabil-
ity of early death (Fig.  6f ). In this regard, our observa-
tion that TF PCA of both intact and disrupted PBMCs 
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was associated with the presence of DIC may point to a 
prognostic role of TF in newly diagnosed AML. However, 
using either the upper limit of normal or the median TF 
PCA level of intact PBMCs as an arbitrary cut-off value, 
we did not observe an effect of increased TF PCA expres-
sion on median or OS in our patient cohort.
Our study has several limitations. First, although the 
total patient cohort is one of the largest so far, the gen-
eralizability of conclusions is still limited by the rela-
tively small sample size of DIC patients. Likewise, much 
larger studies may be required to define the true impact 
of leukemic cell TF PCA expression on clinical outcome 
in newly diagnosed AML. Second, we used a qualita-
tive TGA to measure MP-associated TF PCA. Although 
this assay may adequately mirror TF-driven coagulation 
activation in a plasma environment, quantitative assays 
such as a previously described chromogenic FXa gen-
eration assay [36] may provide more subtle information 
on the role of TF-bearing MPs in AML-associated DIC. 
Third, the impact of induction chemotherapy or treat-
ment with all-trans retinoic acid on TF PCA expression 
and MP shedding was not addressed in our study. Finally, 
albeit novel, our findings on the association of cell-free 
DNA with plasma D-Dimer are rather descriptive, and 
mechanistic studies with functional readouts and differ-
ent methods of DNA isolation and quantification are thus 
required to further define the role of intrinsic contact 
pathway activation in newly diagnosed AML.
Conclusion
Our study clearly shows that PBMC-associated TF PCA 
expression beyond a threshold level inevitably results 
in decompensated DIC in patients with newly diag-
nosed AML. While shedding of TF-bearing MPs is likely 
involved in the pathophysiology of AML-associated 
coagulopathy, additional (i.e. TF-independent) pathways 
contribute to systemic coagulation activation and DIC 
evolution. Of these pathways, liberation of cell-free DNA 
may be a novel mediator of intrinsic contact pathway 
activation in this hematological malignancy.
Methods
Patients
The study protocol was approved by the ethics commit-
tee of the city of Hamburg, Germany (no. OB-059/05), 
and the study was conducted in accordance with the sec-
ond Declaration of Helsinki. All patients and controls 
provided written informed consent.
Patients were eligible if they had been admitted to the 
University Medical Center Hamburg-Eppendorf, Ger-
many, for diagnostic work-up and subsequent treatment 
of presumed AML, which was confirmed by standard 
cytological, cytogenetic, and immunophenotypic criteria 
in 69 patients (Table 1). In five and seven patients, how-
ever, the final diagnoses were ALL or MDS, respec-
tively. These patients served as additional reference 
groups for the analysis of PBMC-associated TF PCA (see 
below). The ALL patient cohort comprised four females 
and one male (mean age, 37 ±  14  years), and the MDS 
patient cohort comprised three females and four males 
(65  ±  9  years). The group of healthy controls (n  =  10) 
included four females and six males (54  ±  18  years). 
Although consecutive patient enrollment was not feasible 
for logistic or consenting reasons, patients were enrolled 
on a random basis between August 2005 and November 
2014, thus grossly representing the population of AML 
patients treated at our institution.
Patients had to be at least 18 years of age with no clini-
cal and laboratory evidence for acute bacterial or viral 
infections or severe hepatic or renal dysfunction. Major 
surgical procedures within the preceding 4  weeks and 
any systemic anticoagulation prior to study enrollment 
were exclusion criteria.
Blood sampling and processing
All blood samples were taken before the initiation of 
specific anti-leukemic therapy. Venous blood was drawn 
by puncture of an antecubital vein or through a central 
venous catheter into plastic tubes prefilled with either 
3.2% (0.109  M) sodium citrate or lithium heparin. Cit-
rate-anticoagulated whole blood was centrifuged for 
18  min at 4,000  rpm (1,200×g) to obtain platelet-poor 
plasma, which was snap-frozen in liquid nitrogen and 
stored in aliquots at −80°C until analysis. Heparin-anti-
coagulated whole blood was used to isolate peripheral 
blood mononuclear cells (PBMCs) as described below.
Measurement of plasma D-dimer and thrombin–
antithrombin (TAT) complexes
Plasma D-dimer and TAT complexes were quantified 
using the Innovance™ D-dimer test on a BCS™ coagula-
tion analyzer and the Enzygnost™ TAT micro kit, respec-
tively (Siemens Healthcare).
Isolation of PBMCs
PBMCs were isolated from heparinized whole blood by 
density gradient centrifugation on Ficoll-Hypaque (Phar-
macia) as previously described [26]. Cells were washed in 
phosphate-buffered saline (PBS), adjusted to 1 × 106/mL, 
and immediately analyzed for TF procoagulant activity 
(PCA).
Measurement of cellular TF PCA
A previously described single-stage clotting assay was 
used to measure TF-specific PCA in PBMCs that were 
either left intact or disrupted by repeated freeze-thawing 
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[47]. Briefly, 100  µL of cell suspension (1  ×  106/mL) 
were incubated with 100  µL of normal human plasma 
(NHP) (HemosIL™; Instrumentation Laboratory) in the 
cuvettes of a KC10 coagulation instrument (Amelung) 
for 2 min at 37°C. Following the addition of CaCl2 (final 
concentration, 5  mM), times until fibrin clot forma-
tion were recorded. All measurements were carried out 
in triplicates in the presence of 30 µg/mL inhibitory TF 
monoclonal antibody (#4509; American Diagnostica) 
or control IgG (Sigma). Clotting times were converted 
into arbitrary PCA units (AU) by reference to a standard 
curve obtained by serial dilutions of lipidated recombi-
nant human TF (Innovin™; Dade Behring).
Measurement of microparticle-associated TF PCA
Plasma microparticles (MPs) were isolated by centrifuga-
tion at 100,000×g for 90 min at 10°C. Pellets were resus-
pended in the original volume with PBS. MP-associated 
TF activity was measured by a TGA according to the 
method developed by Hemker [48, 49]. Briefly, 20 µL of 
MP suspension were added, along with 20 µL of a mix-
ture containing CaCl2 and the fluorogenic substrate 
Z-GGA-AMC-HCl (Bachem BioSciences), to 80  µL 
NHP in the presence of 25 µg/mL corn trypsin inhibitor 
(Enzyme Research Laboratories). Thrombin generation 
was measured over a period of 90 min using a Synergy 2 
fluorometer (BioTek). MP suspensions were added as the 
only source of TF and phospholipids to initiate coagu-
lation. Inhibitory TF antibody H36 (50  µg/mL) (Sunol 
Molecular) was employed to verify TF specificity.
Measurement of plasma TF antigen
Plasma TF antigen was measured using the Quantikine™ 
enzyme-linked immunosorbent assay (ELISA) (R&D Sys-
tems) according to the manufacturer’s instructions.
Measurement of VEGF antigen in plasma and culture 
supernatant
The Quantikine™ ELISA (R&D Systems) was used to 
measure vascular endothelial growth factor (VEGF) 
antigen levels in plasma samples and culture superna-
tants. Supernatants were prepared by incubating isolated 
PBMCs (1  ×  106/mL) for 24  h at 37°C and 5% CO2 in 
RPMI culture medium in the presence of 10% fetal calf 
serum. Cells were removed by centrifugation and super-
natants stored at −80°C until analysis.
Quantification of cell-free plasma DNA
Plasma DNA was quantified based on a previously 
described method [22]. Briefly, 2  µL of plasma were 
diluted in 98  µL of PBS containing 0.1% bovine serum 
albumin. Diluted plasma was then mixed with 100  µL 
PBS containing Sytox™ Green nucleic acid stain (Invitro-
gen) at a final concentration of 2 µM to label DNA fluo-
rescently. Fluorescence was recorded using MTP reader 
(Tecan) with a 485  nm excitation and 535  nm emission 
filter set. Autofluorescence was considered as back-
ground and determined in samples mixed with PBS with-
out Sytox™ Green. DNA concentrations were calculated 
based on a standard curve obtained by known concentra-
tions of DNA.
Statistical analysis
Normally and non-normally distributed data were pre-
sented as mean  ±  standard deviation and median with 
(interquartile) range, respectively. Differences between 
two groups were analyzed using the two-sided Student’s 
t test or the Mann–Whitney U test. Differences between 
multiple groups were analyzed using the Kruskal–Wal-
lis test. Categorical data were analyzed using the Fisher’s 
exact test. Correlation coefficients were according the 
method of Spearman. Kaplan–Meier survival curves 
were compared using the log-rank (Mantel–Cox) test. 
All analyses were carried out using GraphPad Prism™ 
software. A P value of <0.05 was considered statistically 
significant.
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